Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ibogaine/Medicinal Chemistry & Drug Development

Ibogaine for Medicinal Chemistry & Drug Development

17 papers and 1 clinical trial exploring ibogaine as a treatment for medicinal chemistry & drug development.

CompoundIndole Alkaloid

Ibogaine

A unique indole alkaloid with complex pharmacology, investigated primarily for its capacity to interrupt substance use disorders and withdrawal.

Full Ibogaine profile
IndicationOver 300 million people worldwide experience depression, with many also suffering from related anxiety disorders.

Medicinal Chemistry & Drug Development

Medicinal chemistry plays a crucial role in the development of novel psychedelic compounds, focusing on their molecular structures and interactions. Researchers utilise innovative methods to enhance safety and efficacy in psychedelic substances.

Full Medicinal Chemistry & Drug Development profile

Academic Research

17 papers
Open Accessindividual

The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients

This pharmacokinetic study (n=14) on ibogaine (700mg/70kg) for opioid use disorder (OUD) finds significant variability in ibogaine clearance, strongly correlated with CYP2D6 genotype. Ibogaine plasma concentrations correlate with QTc prolongation and cerebellar effects, while neither ibogaine nor noribogaine correlate with the severity of opioid withdrawal symptoms.

Published
March 22, 2024
Journal
Journal of Psychopharmacology
Authors
Knuijver, T., Heine, R. T., Schellekens, A., Heydari, P., Lucas, L., Westra, S., Belgers, M., van Oosteren, T., Verkes, R. J., Kramers, C.
Paywallmeta

Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview

This review (2023) examines ibogaine as a potential treatment for substance use disorders (SUDs). The lack of randomised, controlled studies on its safety and efficacy and the elusive mechanisms of action have been barriers to clinical use. The review suggests that ibogaine and its metabolite, noribogaine (NOR), modulate multiple targets associated with SUDs, emphasizing a complex, multi-target approach to understanding its pharmacology.

Published
November 8, 2023
Journal
Journal of Psychopharmacology
Authors
Ona, G., Reverte, I., Rossi, G. N., Dos Santos, R. G., Hallak, J. E., Colomina, M. T., Bouso, J. C.
Open Accessmeta

Ibogaine - A legacy within the current renaissance of psychedelic therapy

This review (2023) gives an overview of research into ibogaine. It details animal studies and the human use of ibogaine in stopping addiction. Studies are few and far between, and clinical trials are only now being started.

Published
April 1, 2023
Journal
Pharmacological Research
Authors
Mash, D. C.
Open Accessindividual

Novel Class of Psychedelic Iboga Alkaloids Disrupts Opioid Use

This preprint (2023, v2) animal in vivo and human in vitro study examines a new class of oxa-iboga alkaloids (10 & 40 mg/kg) concerning their effects on opioid addiction in rats and their cardiotoxic effects on human heart cells. In contrast to noribogaine, oxa-iboga analogs exhibited no risk of inducing arrhythmia in adult human primary cardiomyocytes, and oxa-noribogaine induced acute and long-lasting suppression of morphine self-administration in rats in response to both single and repeated dosing regimes.

Published
February 15, 2023
Journal
Biorxiv
Authors
Havel, V., Kruegel, A. C., Bechand, B., Mcintosh, S., Stallings, L., Hodges, A., Wulf, M. G., Nelson, M., Hunkele, A., Ansonoff, M., Pintar, J. E., Hwu, C., Abi-Gerges, N., Zaidi, S. A., Katritch, V., Yang, M., Javitch, J. A., Majumdar, S., Hemby, S. E., Sames, D.
Open Accessmeta

The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020)

This review (s=18) did a qualitative analysis of studies with ibogaine and describes the acute adverse events (cardiac, gastrointestinal, neurological) and long-lasting effects (persistent cardiac, psychiatric, neurological). The authors note that phase I studies with standardized products are necessary as the products quantity and mix was widely varied.

Published
August 18, 2021
Journal
Psychopharmacology
Authors
Ona, G., Rocha, J. M., Bouso, J. C., Hallak, J. E., Borràs, T., Colomina, M. T., Dos Santos, R. G.
Open Accessindividual

A Single Administration of the Atypical Psychedelic Ibogaine or Its Metabolite Noribogaine Induces an Antidepressant-Like Effect in Rats

This rodent study investigates behavioral effects of acute ibogaine and noribogaine administration in rats. It found that both produced a dose-and time-dependent antidepressant effect without substantial changes in animal locomotor activity.

Published
April 24, 2020
Journal
ACS Chemical Neuroscience
Authors
Rodríguez, P., Urbanavicius, J., Prieto, J. P., Fabius, S., Reyes, A. L., Havel, V., Sames, D., Carrera, C. S. I.

Clinical Trials

1 trial
CompletedPhase I

The role of CYP2D6 in the pharmacokinetics of ibogaine in healthy volunteers

This randomised, double-blind, placebo-controlled trial (n=24) investigates the role of CYP2D6 in the pharmacokinetics of ibogaine (20mg) in healthy volunteers.

Started
July 1, 2013
Type
interventional
Blinding
single
Randomized
Yes
Registry ID
ACTRN12613000324718

Explore further

Search all Ibogaine papers Search all Medicinal Chemistry & Drug Development trials Full Ibogaine profile Full Medicinal Chemistry & Drug Development profile